Key Takeaways
- Fosun Pharma has outlicensed its inflammatory disease candidate FXS6837 to Sitala Bio for up to $670 million.
- The deal includes $25 million upfront, with additional payments tied to development milestones and sales performance.
- This marks Fosun’s second deal this month focused on inflammatory diseases, following a $645 million agreement with Expedition Therapeutics.
Fosun Pharma’s Latest Strategic Moves
Fosun Pharma has announced the out-licensing of its drug candidate FXS6837 to Sitala Bio, a UK-based biotech startup, in a deal valued at up to $670 million. This agreement was detailed in a securities filing on August 26. The drug, currently in phase 2 development in China, is a small molecule targeting an immune-modulated disease; its potential is underscored by existing treatments in this category generating $3.8 billion in global revenue last year, according to IQVIA data.
Sitala Bio, founded in 2021, aims to combat harmful inflammation related to neurodegenerative and inflammatory diseases. Key investors include Forbion and OrbiMed, with Matt Cooper, a Forbion partner, serving as CEO.
The financial breakdown of the Fosun and Sitala transaction includes a $25 million upfront payment. Fosun stands to earn up to $165 million in development and commercialization milestones, and an additional $480 million based on sales milestones. Furthermore, Fosun will acquire $5 million worth of Sitala shares, which represent less than 10% of Sitala’s total outstanding shares on a fully diluted basis.
This deal comes shortly after Fosun’s earlier agreement with Expedition Therapeutics, valued at up to $645 million, which revolves around the oral drug XH-S004. This drug is under clinical development in China for conditions such as non-cystic fibrosis bronchiectasis and chronic obstructive pulmonary disease. The announcement of this transaction closely followed the FDA’s approval of Insmed’s Brinsupri (brensocatib), marking the first DPP-1 inhibitor to reach the market.
Fosun’s proactive approach to securing innovative drug partnerships is a response to the lagging performance of its older drug portfolio. In its half-year results disclosed on August 26, Fosun reported a 4.7% revenue drop to 19.4 billion Chinese yuan ($2.7 billion). This decline has been attributed to the challenges posed by local government initiatives aimed at volume-based procurement of off-patent drugs.
Overall, these developments indicate Fosun Pharma’s commitment to expanding its pipeline of innovative therapies as it adapts to the changing pharmaceutical landscape and seeks to improve its market performance through strategic partnerships.
The content above is a summary. For more details, see the source article.